Furthermore, FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase inhibitors have been proven to work as successful therapies alone and in conjunction with other modalities in a percentage of lymphoma patients. Here, FLT3 is linked to lymphoma.